Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports

INTRODUCTION: Drug reimbursement decisions are often made based on a price set by the manufacturer. In some cases, this price leads to public and scientific debates about whether its level can be justified in relation to its costs, including those related to research and development (R&D) and ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Enzing, Joost J., Knies, Saskia, Engel, Jop, IJzerman, Maarten J., Sander, Beate, Vreman, Rick, Boer, Bert, Brouwer, Werner B. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434877/
https://www.ncbi.nlm.nih.gov/pubmed/36045377
http://dx.doi.org/10.1186/s12962-022-00383-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434877/
https://www.ncbi.nlm.nih.gov/pubmed/36045377
http://dx.doi.org/10.1186/s12962-022-00383-y

Ejemplares similares